Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

White-Coat Hypertension: the Neglected Subgroup in Hypertension

  • Cuspidi, Cesare (Department of Health Science, Clinica Medica, University of Milano-Bicocca) ;
  • Tadic, Marijana (Department of Cardiology, Charite-University-Medicine Campus Virchow Klinikum) ;
  • Mancia, Giuseppe (Department of Health Science, Clinica Medica, University of Milano-Bicocca) ;
  • Grassi, Guido (Department of Health Science, Clinica Medica, University of Milano-Bicocca)
  • Received : 2018.05.09
  • Accepted : 2018.06.05
  • Published : 2018.07.30
⟨ Previous Next ⟩

Abstract

The clinical prognostic importance of white coat hypertension (WCH), that is, the clinical condition characterized by an increase of office but a normal ambulatory or home blood pressure (BP) is since a long time matter of considerable debate. WCH accounts for a consistent portion of hypertensive patients (up to 30-40%), particularly when hypertension is mild or age is more advanced. Although scanty and inconsistent information is available on the response of office and out-office BP to antihypertensive treatment and the cardiovascular (CV) protection provided by treatment, an increasing body of evidence focusing on the association of WCH with CV risk factors, subclinical cardiac and extra-cardiac organ damage and, more importantly, with CV events indicates that the risk entailed by this condition is intermediate between true normotension and sustained hypertension. This review will address a number of issues concerning WCH with particular attention to prevalence and clinical correlates, relation with subclinical target organ damage and CV morbidity/mortality, therapeutic perspectives. Several topics covered in this review are based on data acquired over the past 20 years by the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study, a longitudinal survey performed by our group on the general population living in the surroundings of Milan area in the north part of Italy.

Keywords

References

  1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc
  2. Hermida RC, Smolensky MH, Ayala DE, Portaluppi F. Ambulatory Blood Pressure Monitoring (ABPM) as the reference standard for diagnosis of hypertension and assessment of vascular risk in adults. Chronobiol Int 2015;32:1329-42. https://doi.org/10.3109/07420528.2015.1113804
  3. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988;259:225-8. https://doi.org/10.1001/jama.1988.03720020027031
  4. Mancia G, Sega R, Bravi C, et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995;13:1377-90.
  5. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension 2018;71:e13-115.
  6. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013;31:1731-68. https://doi.org/10.1097/HJH.0b013e328363e964
  7. Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] study). Circulation 2001;104:1385-92. https://doi.org/10.1161/hc3701.096100
  8. Afsar B. Comparison of demographic, clinical, and laboratory parameters between patients with sustained normotension, white coat hypertension, masked hypertension, and sustained hypertension. J Cardiol 2013;61:222-6. https://doi.org/10.1016/j.jjcc.2012.11.003
  9. Mule G, Nardi E, Cottone S, et al. Metabolic syndrome in subjects with white-coat hypertension: impact on left ventricular structure and function. J Hum Hypertens 2007;21:854-60. https://doi.org/10.1038/sj.jhh.1002238
  10. Tocci G, Presta V, Figliuzzi I, et al. Prevalence and clinical outcomes of white-coat and masked hypertension: analysis of a large ambulatory blood pressure database. J Clin Hypertens (Greenwich) 2018;20:297-305. https://doi.org/10.1111/jch.13181
  11. de la Sierra A, Vinyoles E, Banegas JR, et al. Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. J Hypertens 2017;35:2388-94. https://doi.org/10.1097/HJH.0000000000001493
  12. Vyssoulis G, Karpanou E, Adamopoulos D, et al. Nocturnal blood pressure fall and metabolic syndrome score in patients with white coat hypertension. Blood Press Monit 2008;13:251-6. https://doi.org/10.1097/MBP.0b013e32830719c0
  13. Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009;27:1672-8. https://doi.org/10.1097/HJH.0b013e32832be5f9
  14. Grassi G, Seravalle G, Trevano FQ, et al. Neurogenic abnormalities in masked hypertension. Hypertension 2007;50:537-42. https://doi.org/10.1161/HYPERTENSIONAHA.107.092528
  15. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res 2015;116:976-90. https://doi.org/10.1161/CIRCRESAHA.116.303604
  16. Cuspidi C, Facchetti R, Bombelli M, et al. Risk of new onset metabolic syndrome associated with white coat and masked hypertension: data from a general population. J Hypertens. 2018. [Epub ahead of print].
  17. Siven SS, Niiranen TJ, Kantola IM, Jula AM. White-coat and masked hypertension as risk factors for progression to sustained hypertension: the Finn-Home study. J Hypertens 2016;34:54-60. https://doi.org/10.1097/HJH.0000000000000750
  18. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009;54:226-32. https://doi.org/10.1161/HYPERTENSIONAHA.109.129882
  19. Palatini P, Dorigatti F, Roman E, et al. White-coat hypertension: a selection bias? Harvest Study Investigators. Hypertension and Ambulatory Recording Venetia Study. J Hypertens 1998;16:977-84. https://doi.org/10.1097/00004872-199816070-00011
  20. Cuspidi C, Meani S, Sala C, et al. How reliable is isolated clinical hypertension defined by a single 24-h ambulatory blood pressure monitoring? J Hypertens 2007;25:315-20. https://doi.org/10.1097/HJH.0b013e3280119025
  21. Mancia G, Grassi G. The heterogeneous nature of white-coat hypertension. J Am Coll Cardiol 2016;68:2044-6. https://doi.org/10.1016/j.jacc.2016.08.043
  22. Bombelli M, Facchetti R, Carugo S, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 2009;27:2458-64. https://doi.org/10.1097/HJH.0b013e328330b845
  23. Hoegholm A, Kristensen KS, Bang LE, Nielsen JW, Nielsen WB, Madsen NH. Left ventricular mass and geometry in patients with established hypertension and white coat hypertension. Am J Hypertens 1993;6:282-6. https://doi.org/10.1093/ajh/6.4.282
  24. Cuspidi C, Rescaldani M, Tadic M, Sala C, Grassi G, Mancia G. White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis. J Hypertens 2015;33:24-32. https://doi.org/10.1097/HJH.0000000000000416
  25. Manios E, Michas F, Stamatelopoulos K, et al. White-coat isolated systolic hypertension is a risk factor for carotid atherosclerosis. J Clin Hypertens (Greenwich) 2016;18:1095-102. https://doi.org/10.1111/jch.12888
  26. Mancusi C, Gerdts E, Losi MA, et al. Differential effect of obesity on prevalence of cardiac and carotid target organ damage in hypertension (the Campania Salute Network). Int J Cardiol 2017;244:260-4. https://doi.org/10.1016/j.ijcard.2017.06.045
  27. Cuspidi C, Sala C, Tadic M, Rescaldani M, Grassi G, Mancia G. Is white-coat hypertension a risk factor for carotid atherosclerosis? A review and meta-analysis. Blood Press Monit 2015;20:57-63.
  28. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006;47:846-53. https://doi.org/10.1161/01.HYP.0000215363.69793.bb
  29. Mancia G, Bombelli M, Brambilla G, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension 2013;62:168-74. https://doi.org/10.1161/HYPERTENSIONAHA.111.00690
  30. Mancia G, Facchetti R, Grassi G, Bombelli M. Adverse prognostic value of persistent office blood pressure elevation in white coat hypertension. Hypertension 2015;66:437-44. https://doi.org/10.1161/HYPERTENSIONAHA.115.05367
  31. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 2011;24:52-8. https://doi.org/10.1038/ajh.2010.203
  32. Franklin SS, Thijs L, Hansen TW, et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension 2012;59:564-71. https://doi.org/10.1161/HYPERTENSIONAHA.111.180653
  33. Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol 2015;66:2159-69. https://doi.org/10.1016/j.jacc.2015.09.007
  34. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens 2016;34:593-9. https://doi.org/10.1097/HJH.0000000000000832
  35. Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 2018;378:1509-20. https://doi.org/10.1056/NEJMoa1712231
  36. Hoegholm A, Wiinberg N, Kristensen KS. The effect of antihypertensive treatment with dihydropyridine calcium antagonists on white-coat hypertension. Blood Press Monit 1996;1:375-80.
  37. Bulpitt CJ, Beckett N, Peters R, et al. Does white coat hypertension require treatment over age 80?: Results of the hypertension in the very elderly trial ambulatory blood pressure side project. Hypertension 2013;61:89-94. https://doi.org/10.1161/HYPERTENSIONAHA.112.191791
  38. Fagard RH, Staessen JA, Thijs L, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation 2000;102:1139-44. https://doi.org/10.1161/01.CIR.102.10.1139
  39. Mancia G, Facchetti R, Parati G, Zanchetti A. Effect of long-term antihypertensive treatment on white-coat hypertension. Hypertension 2014;64:1388-98. https://doi.org/10.1161/HYPERTENSIONAHA.114.04278
  40. National Institute for Health and Clinical Excellence (UK). Hypertension in adults: diagnosis and management. Clinical guideline [Internet]. London: National Institute for Health and Clinical Excellence; 2011 [cited 2011 Aug]. Available from: www.nice.org.uk/guidance/CG127.
  41. Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol 2017;33:557-76. https://doi.org/10.1016/j.cjca.2017.03.005
  42. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res 2015;116:1034-45. https://doi.org/10.1161/CIRCRESAHA.116.303755

Cited by

  1. Ambulatory Blood Pressure and Mortality vol.379, pp.13, 2018, https://doi.org/10.1056/nejmc1809851
  2. Achieving control of resistant hypertension: Not just the number of blood pressure medications vol.9, pp.1, 2018, https://doi.org/10.5494/wjh.v9.i1.1
  3. Whose Coat Is It Anyway? : vol.94, pp.4, 2018, https://doi.org/10.1097/acm.0000000000002578
  4. Blood pressure control and cardiovascular risk profile in hypertensive patients under specialist care in Argentina: Results from the CHARTER study vol.21, pp.10, 2019, https://doi.org/10.1111/jch.13684
  5. Effects of white-coat, masked and sustained hypertension on coronary artery stenosis and cardiac arrhythmia vol.43, pp.2, 2020, https://doi.org/10.1038/s41440-019-0342-3